A B S T R A C T Studies were conducted to determine the effects of colestipol hydrochloride, a new bile acidsequestrant resin, on some of the parameters of cholesterol turnover and metabolism in man. Three normal volunteers and eight hyperlipidemic patients participated in three sets of cholesterol turnover studies carried out at intervals of approximately 1 yr. The effects of colestipol were assessed by comparing the results obtained before therapy with those obtained on repeat study after several months of resin therapy. Colestipol treatment significantly reduced the serum cholesterol concentration (mean reduction 21%), and produced a large increase in the production rate of cholesterol (mean 86%) and in the turnover rate of cholesterol in pool 1 (mean 46%). The values of the intercompartmental rate constants and of the size of the rapidly exchangeable pool were unchanged with therapy.
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The turnover studies were carried out for 12-13 wk, and were analyzed according to a two-pool model. Although long-term studies of cholesterol turnover con- form to a three-pool, rather than a two-pool model, the present studies probably provide a valid estimate of the effects of therapy on certain parameters, namely the production rate, the size, and the turnover rate of pool 1. Repeated studies in four untreated subjects showed a striking constancy with time for the kinetic parameters for each subject. The 11 June 1973. four patients, and reduced the triglyceride level in all four patients. Addition of clofibrate to the treatment program produced only small decreases in the production rate, which were not significantly different from the small decreases seen in two patients who were continued (and restudied) on colestipol alone. The findings do not support the suggestion that clofibrate can block the increased rate of cholesterol synthesis and turnover resulting from bile acid-sequestrant treatment. The effects on serum lipids, however, make the combined drug therapy potentially quite useful. INTRODUCTION Considerable information is now available about the turnover of plasma cholesterol in normal and in hyperlipidemic humans. When kinetic studies are conducted for periods of about 10-12 wk, the turnover of cholesterol can be described satisfactorily by a simple twopool model (1) (2) (3) (4) . This model has been used to examine the relationships between some parameters of cholesterol metabolism and other clinical features such as body weight (3) . The kinetic approach has also been employed to assess the effects of drugs that lower serum lipids, such as cholestyramine resin (1, 5, 6) , neomycin (2) , and clofibrate (7) . The effects of ileal bypass surgery on body cholesterol metabolism have been examined by the turnover technique (6, 8) .
More recent studies have demonstrated that much longer studies of cholesterol turnover in man do not fit a two-pool model closely, but require a three-pool model (9) or an alternative approach, input-output analysis, (10, 11) for satisfactory analysis of the data. These studies indicate that certain parameters of cholesterol metabolism, particularly the production rate and the size of the rapidly exchangeable compartment, can be estimated accurately by both medium-and long-term studies, whereas other parameters, such as total body exchangeable cholesterol, can be estimated only poorly. (-) means that the study was not carried out in that subject.
In recent years increasing clinical attention has been focused on drugs that lower serum lipids in hyperlipidemic patients. One effective agent is cholestyramine, an anion-exchange resin that binds bile acids in the intestine and prevents their reabsorption (1, 6, (12) (13) (14) . This drug results in a greatly increased fecal excretion of acidic steroids (6, 14) , and secondarily in an increased catabolism and synthesis of cholesterol and a reduced plasma cholesterol level.
Colestipol hydrochloride (Colestid, U-26,597A, The Upjohn Co., Kalamazoo, Mich.), a new bile acidsequestering resin, is a high-molecular weight, insoluble polyethylenepolyamine polymer with 1-chloro-2,3-epoxypropane, which effectively lowers serum cholesterol in experimental animals and in humans (15--18) . We now report the results of studies carried out to determine the effects of colestipol resin on some of the parameters of cholesterol turnover and metabolism in man. A small number of studies were also conducted to examine the effects of combined drug therapy with colestipol plus clofibrate METHODS 11 volunteer subjects, whose ages and sexes are listed in Table I , participated in these studies. Three of the subjects, F. C., R. M., and R. N., served as normal controls.
The other eight subjects had mild to moderate degrees of hyperlipidemia; their plasma lipid levels, and the types of lipoprotein patterns (19, 20) , seen on lipoprotein electrophoresis (21) at the start of the first study, are given in Table II . Two of the hyperlipidemic patients, G. W. and L. Z., had clinical coronary heart disease, as indicated by previously documented myocardial infarctions. Two of the patients, E. C. and J. G., had asymptomatic hypertension; the other patients were clinically well. All subjects ate their usual diets during each of the studies, and were specifically asked not to modify their diets during the course of these studies. None of the subjects lost or gained significant amounts of weight during a given study. Weight changes exceeding 5% of body weight were, however, seen between studies in three of the subjects, L. Z., A. S., aad G. W.: see Table I .
Three sets of turnover studies, designated studies I, II, and III, were carried out at intervals of approximately 1 yr. In each study [4-'C] cholesterol complexed with serum lipoprotein was injected intravenously, and the specific radioactivity of serum total cholesterol was determined on blood samples collected three times during the first week, and at approximately weekly intervals thereafter for a total of 12-13 wk. In each study, the first two samples were collected 1 day and 3 days, respectively, after isotope injection. The methods used have been described fully previously (1, 9) .
The data from each study were analyzed by digital computer, as described elsewhere (9) , in order to determine the parameters of a two-pool model which would provide the best fit. No improvement in fit was obtained when the data were analyzed according to a three-pool model. We have reported recently (9) that long-term (e.g., 32-41 wk duration) turnover curves conform to a three-pool model, whereas medium-term data (e.g., 12 wk) are satisfactorily described by a two-pool model.
The model used is illustrated in Fig. 1 . The notation is identical with that described elsewhere (9) . The pools are denoted by arabic numbers (pools 1 and 2), rate constants are denoted by k, the rate of transfer of cholesterol mass (in g/day) into or out of a pool is denoted by R, cholesterol production rate (PR) 1 is given by Rm At the time of study I (begun January 1970) no subject was taking a lipid-lowering drug, and all subjects had been in an apparent steady state, with reasonably constant plasma lipid concentrations, for several months. Serum containing approximately 22 ACi of "C-labeled cholesterol was injected into each subject. After the completion of study I, seven of the eight hyperlipidemic subjects were treated with colestipol hydrochloride at a dose of 15 g/day (5 g three times a day). In all of these subjects, resin treatment was continued without interruption for at least 2 yr.
Study II was begun after treatment with colestipol resin had been continued for at least 5 mo (range, 5-9 mo; mean 8 mo) in the subjects under investigation. All subjects had stable plasma lipid levels for several weeks before the start of the study. Each subject was given approximately 24 ,uCi ["C]cholesterol. Several months later four of the patients being treated with colestipol resin were also begun on treatment with clofibrate (Atromid-S, Ayerst Laboratories, Div. of American Home Products Corp., New York) at a dose of 2 g/day (1 g twice daily). A new apparent steady state with regard to plasma lipid levels was reached in less than 4 wk. Study III was begun approximately 8 wk after the start of combined drug therapy (with resin plus clofibrate) in these patients. Each subject was injected with approximately 17 /ACi of [4-jC] cholesterol. The data for all three sets of studies were later adjusted to an injected dose of 25 GCi for each study in each subject, for final data analysis.
The residual radioactivity in the plasma just before the start of study II was very low (specific radioactivity less than 0.3% of that found in the 1-day sample). At the start of study III the residual radioactivity (from the previous two studies) ranged from 0.2 to 0.7% (mean 0.5%) of the level of 'C found in the 1-day sample. In one subject (J. B.) the residual radioactivity was somewhat higher (2% of that of the 1-day sample). The data were corrected for the observed low levels of residual radioactivity; the corrections were extremely small in every instance.
Statistical analysis of the results obtained in the three series of studies was carried out by comparing the change in each of the parameters of the model (PR, k, and M, see Fig. 1 ) to the changes observed for these parameters in the untreated subjects by the t test for uncorrelated samples. The significance of the change in parameters seen when resin was continued alone in study III was assessed by an analysis of variance (22) . Table II ). Treatment with colestipol resin resulted in a highly significant reduction of the serum cholesterol concentration in every treated subject (see Table II ). The average reduction (study II as compared to study I) was 21 .1% (range 36.6%-5.7%). Statistically significant changes were also seen in the serum triglyceride concentrations of six of the seven treated subjects. The direction of the change in triglyceride level was, however, not consistent: four subjects showed significant decreases in triglyceride levels, whereas two subjects showed significant increases (Table II) .
Addition of clofibrate to treatment with colestipol resin resulted in a highly significant further reduction in both the serum cholesterol and triglyceride concentrations in three of the four patients so treated. In these three subjects (J. G., H. G., and A. S.) the mean cholesterol concentrations during Study III were 68.9%, 73.4%, and 60.5% of those observed during study I (see Table II ). In the fourth patient (G. W.) the mean serum cholesterol level during study III did not differ from that during study II, although the combined drug treatment did produce a lower triglyceride level than that seen with resin alone.
Two subjects, E. C. and H. L., were continued on colestipol treatment alone, without the addition of clofibrate. Serum cholesterol and triglyceride concentrations rose between studies II and III in both of these subjects. The serum cholesterol concentrations remained, however, highly significantly reduced (by 17% and 24%, respectively) when compared to the values seen in study I, before treatment (see Table II ).
Untreated control subjects. The reproducibility of the kinetic parameters for any given subject was examined by repeat studies in untreated subjects. The results are shown in Table III . Two subjects were studied in all three sets of studies. Two subjects were studied in two of the three sets of studies; in addition, data were available for one of these latter subjects from a turnover study carried out in 1966. Inspection of the results (Table III) ach subject for final data parameters listed. The estimates of PR in pool 1 were the most constant, and those of the limiting values of M, and of pool 2 turnover rate (km) were the least constant from study to study for a given subject.
Effects of colestipol therapy. The effects of colestipol therapy were assessed by comparing the results obtained without therapy (study I) with those obtained during resin therapy (study II) in the seven subjects who were studied under both conditions. The results are presented in Table IV (Table III) . The control differences were drawn randomly from the untreated group so that each subject contributed only once to the differences. The increases in the production rate and in ku were both highly significant (P < 0.01).
With this rigorous statistical analysis, none of the other parameters of the two-pool model ( Fig. 1 [4-"C]cholesterol (study III). Blood samples were col-humans. Colestipol was well tolerated, without signifilected for an additional 6-7 wk, in order to determine cant side effects, in all seven subjects during the 2-yr the corresponding data points for the turnover curve. period of drug administration. The effects of colestipol On discontinuing clofibrate the serum cholesterol levels were assessed by comparing the results of cholesterol rose within 1 wk. and remained fairly stable there-turnover studies carried out without (before) therapy after, at mean levels which were 16% and 9% higher with those obtained on repeat study after several than the mean levels observed during the first 13 wk months of resin therapy. It was assumed that a new of study. The effects on the turnover curve of subject steady state had been achieved by the time the second J. G. are shown in Fig. 2 . Similar results were ob-study was carried out. It is recognized, however, that tained with the other subject. Along with the rise in this assumption may not be completely valid. Colestipol serum cholesterol level, on stopping clofibrate there was treatment resulted in a significant reduction in serum a decrease in the slope of the turnover curve in both cholesterol concentration (mean reduction 21%, range of the subjects. 36%-6%). This was observed in every subject, regardless of lipoprotein phenotype, since the series included DISCUSSION patients with the patterns of Types IIA, IIB, and IV. A These studies were designed to examine the effects of number of the kinetic parameters, of the turnover curve treatment with colestipol resin on some aspects of and the two-pool model, were altered by therapy. The cholesterol metabolism and turnover in hyperlipidemic largest effects seen were increases in the production rate III  II  III  II  III  II  III  II  III  II  III  II  III CT cQ II  III  II  III  II  III  II  III   II   III   II   III  II   III  CT C +At   C C +A C C +A C C +A C C +A C C +A C C +A J. G. (mean 86%), and in the turnover rate of pool 1 (kri, mean 46%). These effects are comparable to the effects of cholestyramine resin treatment, previously reported for a smaller series of subjects (1 three-pool rather than a two-pool model (9) . The longterm studies (9) included data collected during a continuation of study I in five of the subjects reported here (the untreated control subjects F. C., R. M., R. N., and J. B., and patient H. L.). In the previous report (9) Since the three sets of studies reported here were all carried out for the same medium-term duration, it is likely that the studies can be compared with each other, and that they provide a quantitatively valid estimate of the effects of therapy on certain parameters, namely the production rate, the size, and the turnover rate of pool cholesterol, therefore, an increased rate of hepatic biosynthesis would be anticipated. Decreased absorption of cholesterol, reflected in an increased excretion of neutral sterol, has, however, been seen in some but not in all patients studied (6, 14) . Accordingly, other effects of the resin on hepatic synthesis of cholesterol are probably also involved. These effects remain to be defined, but may relate to the increased rate of cholesterol catabolism to bile acids, and the increased rate of turnover and presumably decreased hepatic pool size of bile acids, which occur with resin therapy.
The increased rates of cholesterol synthesis in intestinal mucosa and liver, and of cholesterol conversion to bile acids result in the development of a new steady state during drug therapy, characterized by an increased rate of turnover of cholesterol. The extent of this increase has been quantitatively defined in this study by determining the effect of colestipol resin on the production rate. Along with these changes there also occurs a decrease in the level of plasma cholesterol. The mechanisms responsible for the reduction in plasma cholesterol concentration are not understood. In the present series, there was no correlation between the extent of the increase in production rate with resin therapy and the decrease in serum cholesterol level, when the parameter changes were examined in either relative or absolute terms. Moreover, resin treatment did not affect the size of the entire rapidly exchangeable pool, but only of that small portion of it represented by plasma cholesterol. It is likely that the metabolic changes induced by resin treatment in some way affect the metabolism of plasma lipoproteins, resulting in a consistent lowering in the plasma cholesterol level. This effect provides the basis for the therapeutic usefulness of sequestrant resin in the treatment of hypercholesterolemia.
Repeated studies in four untreated subjects demonstrated that there was a striking constancy with time for the kinetic parameters for each subject. The production rate was particularly constant from year to year for a given subject, and showed a pooled standard deviation of only 0.03 g/day (a coefficient of variation of less than 3%), despite the fact that the values from subject to subject differed by as much as 60% (subject R. M. as compared to J. B., Table III ). Reproducibility of kinetic parameters in a single subject studied on two occasions was previously observed by Samuel, Holtzman, Meilman, and Perl (2). These findings suggest that the total body turnover of cholesterol is under close homeostatic control in an integrated manner. The nature of this control is obscure, since the two major cholesterol-synthesizing tissues, mucosa and liver, appear to be regulated by different mechanisms (31, also see above), and since cholesterol synthesis can occur in a wide range of other tissues. More information is needed about factors that can integrate the control of cholesterol turnover in different tissues: a variety of factors, including genetic, dietary, and metabolic ones, are probably involved.
Increased plasma triglyceride levels in some patients have been reported previously during cholestyramine (6, 32) and during colestipol therapy (16) (17) (18) . In the present study four subjects showed significant decreases and two showed significant increases (Table II) (7, 34) . Clofibrate is known to have a number of effects on cholesterol metabolism. These include the inhibition of cholesterol biosynthesis in the liver (35) (36) (37) , and the enhancement of cholesterol excretion in bile and feces in patients on sterol balance study (7) . It has been suggested (7) that clofibrate can also inhibit cholesterol synthesis in the intestinal mucosa of man and, furthermore, can reduce the rate of mucosal cholesterol synthesis that had been increased by cholestyramine; this suggestion was based on data on the specific radioactivity of mucosal cholesterol. Studies of the effect of clofibrate on the turnover of plasma cholesterol have demonstrated a flattening of the slope of the turnover curvre when clofibrate was administered (7, 38, 39) . The interpretation of this finding is uncertain, although it has been considered to reflect inhibition of cholesterol synthesis or mobilization of cholesterol from tissue pools. In addition, clofibrate has significant and important effects on plasma triglyceride and very low-density lipoprotein metabolism (40, 41) .
The combination of bile acid sequestrant plus clofibrate would seem to be rational since, from the published reports cited, clofibrate could be expected to inhibit partly the increased rate of cholesterol synthesis and turnover induced by the resin sequestrant. Such an inhibition would presumably result in a period of negative sterol balance and a reduction in body pools of cholesterol. It was thus anticipated in the present study that combined drug therapy would result in a significant reduction in the production rate, as compared to the results obtained with colestipol resin alone. Surprisingly, however, only small decreases in production rate were observed in two patients (0.22 and 0.46 g/day, Table V) , and the production rate did not change in the third patient studied. The change in production rate bore no apparent relationship to the change in serum cholesterol level (mean decrease of 45, 43, and 53 mg/100 ml in the three patients, Table II ) produced by addition of clofibrate to therapy. The change in the production rate in these patients was not significantly lifferent from the small decreases in production rate (0.25 and 0.30 g/day, Table V) seen in the two patients who had been continued (and restudied) on resin alone. Although the number of patients studied was small, the statistical analysis employed, comparison of a group of two vs. three patients with the observed SEM of parameter values, could have demonstrated a statistically significant effect of clofibrate if the patients on combined drug treatment had shown a mean decrease in production rate of 0.52 g/day more than did the patients on resin alone. These findings are not consistent with the interpretation that clofibrate was blocking the increased rate of cholesterol synthesis and turnover resulting from colestipol treatment. Because of the small number of studies, however, these results should not be considered as disproving the earlier interpretation, and further studies will be required to resolve this question.
On discontinuing clofibrate there was a decrease in the slope of the turnover curves (Fig. 2) 
